Mutual Funds
Mutual Funds
Fund Profile
Scheme Profile
Daily NAV
Historical NAV
Category Returns
Dividend Details
Fund Ranking
MF Activities
All Holdings
What's In / What's Out
MF Trends
MF Tools
  Home   >   MUTUAL FUND  >  MUTUAL FUNDS  >  CATEGORY RETURNS
CATEGORY RETURNS      
AMC : Category : Scheme :
Nippon India Nifty Pharma ETF
TypeInvestment In% of NAVNo. of sharesValue (Rs cr)
Domestic EquitiesSun Pharmaceutical Industries Limited21.92921336393232.1315
Domestic EquitiesDivi's Laboratories Limited9.7086160366102.7706
Domestic EquitiesDr. Reddy's Laboratories Limited9.345776909598.9287
Domestic EquitiesCipla Limited9.043971009195.7345
Domestic EquitiesLupin Limited6.653330595670.4280
Domestic EquitiesTorrent Pharmaceuticals Limited5.403613200157.2000
Domestic EquitiesLaurus Labs Limited4.983549036352.7533
Domestic EquitiesAurobindo Pharma Limited4.069835300343.0805
Domestic EquitiesAlkem Laboratories Limited3.93447384941.6471
Domestic EquitiesGlenmark Pharmaceuticals Limited3.836419005940.6099
Domestic EquitiesBiocon Limited3.316990073735.1107
Domestic EquitiesMankind Pharma Limited3.031114275532.0856
Domestic EquitiesZydus Lifesciences Limited2.749931582029.1091
Domestic EquitiesIPCA Laboratories Limited2.533617541526.8192
Domestic EquitiesJB Chemicals & Pharmaceuticals Limited2.002210321121.1944
Domestic EquitiesGland Pharma Limited1.729110044418.3029
Domestic EquitiesAbbott India Limited1.6514658917.4806
Domestic EquitiesAjanta Pharma Limited1.50375316615.9174
Domestic EquitiesWockhardt Limited1.341410425914.1990
Domestic EquitiesPiramal Pharma Limited1.151878092812.1926
Total 99.9193 1057.6956
Cash & Cash Equivalents and Net AssetsTriparty Repo0.1272 1.3461
Cash & Cash Equivalents and Net AssetsCash Margin - CCIL0.0008 0.0083
Cash & Cash Equivalents and Net AssetsNet Current Assets-0.0473 -0.5006
Total 0.0807 0.8538
 
Back Back TopTop
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Smart ODR Portal | Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst | UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.